

UBS (CH) Institutional Fund – Equities Global Screened Passive II I-X-dist

Portrait

- Regulation / Supervision: CISA / FINMA (Funds for qualified investors).
- Authorised investors: pension funds, insurance companies, family offices and institutional investors under CISA.
- Investments: Equity securities issued by major companies in established markets worldwide, which are listed in the MSCI World ex Switzerland ESG Screeed Index.
- No investments in securities on the recommendation list for the exclusion of SVVK-ASIR (www.svvk-asir.ch) and controversial weapons.
- Convertible and warrant bonds: none.
- Portfolio is passively managed and aims to replicate the performance of the benchmark.
- Currency exposure: in line with securities portfolio.
- Securities lending: not permitted.
- Use of derivatives: permitted under BVV2.
- All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. Please consult your client advisor for more information on the investment risks of this product.

| Securities no. | | 121,384,321 |
|----------------------------|-------------------------|--------------------------|
| ISIN | | CH1213843217 |
| Bloomberg Ticker | | UEESDIX SW |
| Currency of account | | CHF |
| Issue/redemption | | daily |
| Admin/Custody fees | | none |
| Dilution Levy in Favou | ır of the Fund in/out | 0.04%/0.01% |
| PM fees charged to the NAV | | none |
| TER (as of 31.10.202) | 3) | 0.01% |
| Benchmark | MSCI World ex Switzerla | and ESG Screened Index |
| | | (net div. reinv.) in CHF |

Current data

| Net asset value 31.12.2024 | CHF | 1,307.65 |
|-------------------------------|-----|----------|
| – high last 12 months | CHF | 1,330.38 |
| – low last 12 months | CHF | 1,012.32 |
| Assets of the unit class in m | CHF | 272.96 |
| Fund assets in m | CHF | 451.76 |


Key risk figures (annualised)

| | 2 years | 3 years |
|--|---------|---------|
| Tracking error | n.a. | n.a. |
| Beta | n.a. | n.a. |
| Correlation | n.a. | n.a. |
| Total risk | n.a. | n.a. |
| Sharpe ratio | n.a. | n.a. |
| Risk-free rate (2 years) = 1.37% | | |
| The statistical ratios were calculated on the basis of logarithmic returns | i. | |

Performance (in %)

| | Fund | Benchmark |
|--|-------|-----------|
| 01.2024 | 3.39 | 3.40 |
| 02.2024 | 7.46 | 7.48 |
| 03.2024 | 5.40 | 5.40 |
| 04.2024 | -2.22 | -2.22 |
| 05.2024 | 2.81 | 2.82 |
| 06.2024 | 2.11 | 2.10 |
| 07.2024 | -0.63 | -0.62 |
| 08.2024 | -1.13 | -1.12 |
| 09.2024 | 1.45 | 1.44 |
| 10.2024 | 0.64 | 0.60 |
| 11.2024 | 6.91 | 6.92 |
| 12.2024 | 0.54 | 0.54 |
| 2024 | 29.62 | 29.62 |
| 2023 (since launch 01.2023) since end of fund launch month | 7.64 | 7.70 |
| 01.2023 | 39.52 | 39.60 |

Indexed performance



UBS (CH) Institutional Fund – Equities Global Screened Passive II I-X-dist
 MSCI World ex Switzerland ESG Screened Index (net div. reinv.) in CHF

Past performance is no guarantee of future trends. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units.

Market exposure (in %)

| | Fund | Benchmark |
|----------------|--------|-----------|
| United States | 76.34 | 75.67 |
| Japan | 5.82 | 5.79 |
| Canada | 2.80 | 2.88 |
| United Kingdom | 2.50 | 3.28 |
| Germany | 2.15 | 2.18 |
| France | 1.99 | 2.46 |
| Australia | 1.57 | 1.64 |
| Netherlands | 1.06 | 1.17 |
| Sweden | 0.81 | 0.80 |
| Denmark | 0.76 | 0.74 |
| Others | 4.20 | 3.39 |
| Total | 100.00 | 100.00 |

UBS (CH) Institutional Fund – Equities Global Screened Passive II I-X-dist

Sectors (in %)

| | Fund | Benchmark |
|----------------------------|--------|-----------|
| Energy | 1.64 | 1.94 |
| Materials and supplies | 2.69 | 2.75 |
| Industrials | 9.69 | 9.86 |
| Consumer discretionary | 12.09 | 12.19 |
| Consumer staples | 3.62 | 3.65 |
| Health care | 10.55 | 10.55 |
| Financial system | 16.97 | 17.17 |
| IT | 28.99 | 28.93 |
| Telecommunication services | 8.85 | 8.85 |
| Utilities | 1.81 | 1.82 |
| Real estate | 2.27 | 2.29 |
| Others | 0.83 | 0.00 |
| Total | 100.00 | 100.00 |

10 largest positions (in %)

| | Fund | Benchmark |
|--------------------|-------|-----------|
| Apple | 6.03 | 6.04 |
| NVIDIA Corp | 5.22 | 5.22 |
| Microsoft | 4.72 | 4.72 |
| Alphabet Inc | 3.28 | 3.28 |
| Amazon.com Inc | 3.28 | 3.29 |
| Top 5 | 22.53 | 22.55 |
| Meta Platforms Inc | 2.03 | 2.03 |
| Tesla Inc | 1.84 | 1.84 |
| Broadcom Inc | 1.63 | 1.63 |
| JPMorgan Chase | 1.08 | 1.08 |
| Eli Lilly & Co | 0.99 | 0.99 |
| Top 10 | 30.10 | 30.12 |

Currency exposure (in %)

| | Fund | Benchmark |
|-------|--------|-----------|
| USD | 75.78 | 75.95 |
| EUR | 8.16 | 7.81 |
| JPY | 5.82 | 5.79 |
| GBP | 3.06 | 3.28 |
| CAD | 2.84 | 2.88 |
| AUD | 1.64 | 1.64 |
| SEK | 0.87 | 0.80 |
| DKK | 0.76 | 0.74 |
| HKD | 0.43 | 0.44 |
| SGD | 0.35 | 0.35 |
| NOK | 0.14 | 0.15 |
| ILS | 0.12 | 0.12 |
| NZD | 0.04 | 0.05 |
| Other | -0.01 | 0.00 |
| Total | 100.00 | 100.00 |



For marketing and information purposes by UBS. For professional clients / qualified investors only. UBS funds under Swiss law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned herein in any of the securities or sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and

Additional information to investors in specific countries: Switzerland: Only occupational pension schemes domiciled in Switzerland, their asset managers (for the assets of these institutions) and other investment foundations are eligible investors in investment foundations, in accordance with the Ordinance on Investment Foundations (ASV). Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/an-plossary.

www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary.

© UBS 2025. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.